So now Teva is done & Pfizer has scuttled back into its shell what are we left with in this New Bold Allergan.
In very simple terms, we are left with the Old Allergan with a few additional products bolted on.....the difference is the company is now led by BOLD leaders who constantly need to massage their BOLD egos by playing with people's jobs creating uncertainty.
Allergan Leadership has been moved out (most ran for the hills as best they could with their pockets full of $$$)
Since the takeover the business has been on hold, lack of investment due to Teva & Pfizer. Infrastructure changes have proved to be complex, innovation almost disappeared completely.
How long before there is added complexity with another ego boosting purchase, after all these deals can be done with just a phone call (Teva)
Maybe a period of stability would be better for the long term, to get the back office operational and to provide accurate financial statements. Yes this would hit the share price, but if done correctly there wouldn't be a crash unless there is something hidden in the numbers (I don't think this would be the case).
Perhaps being BOLD is looking at what made Allergan a business worth buying, but I fear that being BOLD means giving the share holders quick returns with an exit strategy still being to sell up shop.
Interesting year ahead!
In very simple terms, we are left with the Old Allergan with a few additional products bolted on.....the difference is the company is now led by BOLD leaders who constantly need to massage their BOLD egos by playing with people's jobs creating uncertainty.
Allergan Leadership has been moved out (most ran for the hills as best they could with their pockets full of $$$)
Since the takeover the business has been on hold, lack of investment due to Teva & Pfizer. Infrastructure changes have proved to be complex, innovation almost disappeared completely.
How long before there is added complexity with another ego boosting purchase, after all these deals can be done with just a phone call (Teva)
Maybe a period of stability would be better for the long term, to get the back office operational and to provide accurate financial statements. Yes this would hit the share price, but if done correctly there wouldn't be a crash unless there is something hidden in the numbers (I don't think this would be the case).
Perhaps being BOLD is looking at what made Allergan a business worth buying, but I fear that being BOLD means giving the share holders quick returns with an exit strategy still being to sell up shop.
Interesting year ahead!